Catheter-related bacteremia in hemodialysis patients: The role of the central venous catheter in prevention and therapy

International Journal of Artificial Organs

Volumn 31, Issue 9, 2008, Pages 827-833

  Troidle, Laura ^a,c   Finkelstein, F O ^a,b  

^a HOSPITAL OF SAINT RAPHAEL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Metabolism Associates   (United States)

Author keywords

Bacteremia; Biofilm; Catheter; Hemodialysis; Outcome

Indexed keywords

ANTIBIOTICS; CATHETERS; DIALYSIS; DISEASE CONTROL; DISEASES; HEMODIALYZERS; PATIENT TREATMENT;

% REDUCTIONS; ANTIBIOTIC THERAPY; BACTERIAL BIOFILM; END-STAGE RENAL DISEASE; GUIDEWIRES; HAEMODIALYSIS; HEMODIALYSIS CATHETER; HEMODIALYSIS PATIENT; OUTCOME; S. AUREUS;

BIOFILMS;

ALCOHOL; ANTIBIOTIC AGENT; CEFOTAXIME; CIPROFLOXACIN; CITRATE SODIUM; CITRATE TRISODIUM; CITRIC ACID; EDETIC ACID; EPEREZOLID; GENTAMICIN; HEPARIN; LEPIRUDIN; LINEZOLID; LOW MOLECULAR WEIGHT HEPARIN; MINOCYCLINE; PSEUDOMONIC ACID; RIFAMPICIN; SALICYLATE SODIUM; TAUROLIDINE; TISSUE PLASMINOGEN ACTIVATOR; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BIOFILM; CATHETER INFECTION; CATHETER REMOVAL; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMBINATION CHEMOTHERAPY; DIALYSIS CATHETER; DRUG EFFICACY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; GRAM NEGATIVE BACTERIUM; GUIDE WIRE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; INDWELLING CATHETER; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; KIDNEY FAILURE; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; RECURRENCE RISK; RISK REDUCTION; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 56349101574     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880803100911     Document Type: Article

References (31)

1. US Renal Data System: USRDS 2005 Annual Data Report. Bethesda, MD: National Institutes of Health, Department of Health and Human Services, 2005.
2. Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and ali-cause mortality: a propensity score analysis. J Am Soc Nephrol 2004; 15: 477-86.
3. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 2001; 60: 1443-51.
4. Mokrzycki MH, Zhang M, Cohen H, Golestaneh L, Laut JM, Rosenberg SO. Tunnelled haemodialysis catheter bacteraemia: risk factors for bacteraemia recurrence, infectious complications and mortality. Nephrol Dial Transplant 2006; 21: 1024-31.
5. Marr KA, Sexton D, Conlon P, Schwab SJ, Kirkland K. Bacteremia in patients with central venous catheters used for hemodialysis: lack of efficiency of catheter salvage. Ann Intern Med 1997; 127: 275-80.
6. Saad TF. Bacteremia associated with tunneled, cuffed hemodialysis catheters. Am J Kidney Dis 1999; 34: 1114-24.
7. Beathard GA. Management of bacteremia associated with tunneled-cuffed hemodialysis catheters. J Am Soc Nephrol 1999; 10: 1045-9.
8. Robinson D, Suhocki P, Schwab SJ. Treatment of infected tunneled venous access hemodialysis catheters with guidewire exchange. Kidney Int 1998; 53: 1792-4.
9. Nissenson AR, Dylan ML, Griffiths RI, Yu HT, Dean BB, Danese MD, Dubois RW. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis. Am J Kidney Dis 2005; 46: 301-8.
10. Inrig JK, Reed SD, Szczech LA, Engemann JJ, Friedman JY, Corey GR, Schulman KA, Reller LB, Fowler VG. Relationship between clinical outcomes and vascular access type among hemodialysis patients with Staphylococcus aureus bacteremia. Clin J Am Soc Nephrol 2006; 1: 518-24.
11. Troidle L, Eisen T, Pacelli L, Finkelstein F. Complications associated with the development of bacteremia with Staphylococcus aureus. Hemodial Int 2007; 11: 72-5.
12. Beasley C, Rowland J, Spergel L. Fistula First: an update for renal providers. Nephrol News Issues 2004; 18: 88, 90.
13. Johnson DW, MacGinley R, Kay TD, Hawley CM, Campbell SB, Isbel NM, Hollett P. A randomized controlled trial of topical exit site mupirocin application in patients with tunneled, cuffed haemodialysis catheters. Nephrol Dial Transplant 2002; 17: 1802-7.
14. Costerton B. Microbial ecology comes of age and joins the general ecology community. Proc Natl Acad Sci USA 2004; 101: 16983-4.
15. Hoyle BD, Jass J, Costerton JW. The biofilm glycocalyx as a resistance factor. J Antimicrob Chemother 1990; 26: 1-5.
16. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. Microbial biofilms. Annu Rev Microbiol 1995; 49: 711-45.
17. Boles BR, Thoendel M, Singh PK. Self-generated diversity produces "insurance effects" in biofilm communities. Proc Natl Acad Sci USA 2004; 101: 16630-5.
18. Messing B, Peitra-Cohen S, Debure A, Beliah M, Bernier JJ. Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. J Parenter Enteral Nutr 1988; 12: 185-9.
19. Dogra GK, Herson H, Hutchison B, Irish AB, Heath CH, Golledge C, Luxton G, Moody H. Prevention of tunneled hemodialysis catheter-related infections using catheter-restricted filling with gentamicin and citrate: a randomized controlled study. J Am Soc Nephrol 2002; 13: 2133-9.
20. Bleyer AJ, Mason L, Russell G, Raad II, Sherertz RJ. A randomized, controlled trial of a new vascular catheter flush solution (minocycline-EDTA) in temporary hemodialysis access. Infect Control. Hosp Epidemiol 2005; 26: 520-4.
21. Nori US, Manoharan A, Yee J, Besarab A. Comparison of low-dose gentamicin with minocycline as catheter lock solutions in the prevention of catheter-related bacteremia. Am J Kidney Dis 2006; 48: 596-605.
22. Saxena AK, Panhotra BR, Sundaram DS, Al-Hafiz A, Naguib M, Venkateshappa CK, Abu-Oun BA, Hussain SM, AlGhamdi AA. Tunneled catheters' outcome optimization among diabetics on dialysis through antibiotic-lock placement. Kidney Int 2006; 70: 1629-35.
23. Al-Hwiesh A, Abdul-Rahman IS. Successful prevention of tunneled, central venous catheter infection by antibiotic lock therapy using vancomycin and gentamycin. Saudi J Kidney Dis 2007; 18: 239-47.
24. Weijmer MC, van den Dorpel M, Van de Ven PJ, ter Wee PM, van Geelen JA, Groeneveld JO, van Jaarsveld BC, Koopmans MG, le Poole CY, Schrander-Van der Meer AM, Siegert CE, Stas KJ; CITRATE Study Group. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol 2005; 16: 2769-77.
25. Weijmer MC, Debets-Ossenkopp YJ, van de Vondervoort FJ, ter Wee PM. Superior antimicrobial, activity of trisodium citrate over heparin for Catheter locking. Nephrol Dial Transplant 2002 17: 2189-95.
26. Kite P, Eastwood K, Sugden S, Percival SL. Use of in vivo-generated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro. J Clin Microbiol 2004; 42: 3073-6.
27. Sherertz RJ, Boger MS, Collins CA, Mason L, Raad II. Comparative in vitro efficacies of various catheter lock solutions. Antimicrob Agents Chemother 2006; 50: 1865.
28. Shah CB, Mittelman MW, Costerton JW, Parenteau S, Pelak M, Arsenault R, Mermel LA. Antimicrobial activity of a novel catheter lock solution. Antimicrob Agents Chemother 2002; 46: 1674-9.
29. Polonio RE, Mermel LA, Paquette, Sperry JF. Eradication of biofilm-forming Staphylococcus epidermidis (RP62A) by a combination of sodium salicylate and vancomycin. Antimicrob Agents Chemother 2001; 45: 3262-6.
30. Curtin J, Cormican M, Fleming G, Keelehan J, Colleran E. Linezolid compared with eperezolid, vancomycin, and gen tamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infection. Antimicrob Agents Chemother 2093; 47: 3145-8.
31. Shanks RM, Sargent JL, Martinez RM, Graber ML, O'Toole GA. Catehter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant 2006; 21: 2247-55.